ACE inhibitor and angiotensin II type 1 receptor antagonist therapies in elderly patients with diabetes mellitus: Are they underutilized?

Drugs and Aging

Volumn 27, Issue 2, 2010, Pages 87-94

  Pappoe, Lamioko Shika ^a   Winkelmayer, Wolfgang C ^a  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

ACE inhibitors, therapeutic use; Angiotensin II receptor antagonists, therapeutic use; Diabetes mellitus; Diabetic nephropathies, prevention; Drug utilisation; Elderly; Kidney disorders

Indexed keywords

ACETYLSALICYLIC ACID; ANGIOTENSIN 2 RECEPTOR ANTAGONIST; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CREATININE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; POTASSIUM; THIAZIDE DIURETIC AGENT;

AGED; BLOOD PRESSURE REGULATION; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; COMORBIDITY; CREATININE BLOOD LEVEL; DIABETES MELLITUS; DISEASE COURSE; DRUG EFFECT; DRUG USE; DRUG UTILIZATION; HEALTH CARE COST; HUMAN; HYPERKALEMIA; HYPERTENSION; KIDNEY DISEASE; KIDNEY FUNCTION; LIFE EXPECTANCY; NOTE; PATIENT MONITORING; PRACTICE GUIDELINE; PRIORITY JOURNAL; PROPHYLAXIS; RISK FACTOR; RISK REDUCTION; TREATMENT INDICATION;

ADULT; AGED; ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ANTIHYPERTENSIVE AGENTS; BLOOD PRESSURE; CREATININE; DIABETES MELLITUS; DIABETIC NEPHROPATHIES; DRUG UTILIZATION; HEALTH SERVICES FOR THE AGED; HUMANS; HYPERKALEMIA; HYPERTENSION; PRACTICE GUIDELINES AS TOPIC; RENIN-ANGIOTENSIN SYSTEM;

EID: 77149130187     PISSN: 1170229X     EISSN: 11791969     Source Type: Journal    
DOI: 10.2165/11316430-000000000-00000     Document Type: Note

References (38)

1. IDF diabetes atlas. Brussels: International Diabetes Federation, 2005 [online]. Available from URL: http://www.eatlas. idf.org [Accessed 2008 May 13]
2. Geiss LS, Herman WH, Goldschmid MG, et al. Surveillance for diabetes mellitus: United States, 1980-1989. MMWR CDC Surveill Summ 1993; 42 (2): 1-20
3. Centers for Disease Control and Prevention (CDC). Racial differences in trends of end-stage renal disease, by primary diagnosis: United States, 1994-2004. MMWR Morb Mortal Wkly Rep 2007; 56 (11): 253-256
4. Boyle JP, Honeycutt AA, Narayan KM, et al. Projection of diabetes burden through 2050: impact of changing demography and disease prevalence in the US. Diabetes Care 2001; 24 (11): 1936-1940
5. Harris MI, Flegal KM, Cowie CC, et al. Prevalence of diabetes, impaired fasting glucose, and impaired glucose tolerance in US adults: the Third National Health and Nutrition Examination Survey, 1988-1994. Diabetes Care 1998; 21 (4): 518-524
6. USRDS. Annual data report: atlas of end-stage renal disease in the US National Institutes of Health. Bethesda (MD): National Institutes of Diabetes and Digestive Kidney Diseases, 2006
7. Engelgau MM, Geiss LS, Saaddine JB, et al. The evolving diabetes burden in the United States. Ann Intern Med 2004; 140 (11): 945-950
8. Centers for Disease Control and Prevention. Diabetes surveillance system. Atlanta (GA): US Department of Health and Human Services, 2003
9. US Centers for Disease Control and Prevention. National diabetes fact sheet: general information and national estimates on diabetes in the United State, 2005. Atlanta (GA): US Department of Health and Human Services, Centers for Disease Control and Prevention, 2005
10. American Diabetes Association. Standards of medical care for patients with diabetes mellitus. Diabetes Care 2008; 31: S55-60
11. Guidelines for improving the care of the older person with diabetes mellitus. California Healthcare Foundation/ American Geriatrics Society Panel on Improving Care for Elders with Diabetes. J Am Geriatr Soc 2003; S1: S265-80
12. Wingard DL, Barret-Conner E. Heart disease and diabetes. In: Harris MI, Cowie CC, Stern MP, et al., editors. Diabetes in America. 2nd ed. Bethesda (MD): National Institutes of Health, 1995: 429-488
13. Hogan P, Dall T, Nikolov P, American Diabetes Association. Economic costs of diabetes in the US in 2002. Diabetes Care 2003; 26 (3): 917-932
14. Bjorck S, Nyberg G, Mulec H, et al. Beneficial effects of angiotensin converting enzyme inhibition on renal function in patients with diabetic nephropathy. Br Med J (Clin Res Ed) 1986; 293 (6545): 471-474
15. Hommel E, Parving HH, Mathiesen E, et al. Effect of captopril on kidney function in insulin-dependent diabetic patients with nephropathy. Br Med J (Clin Res Ed) 1986; 293 (6545): 467-470
16. Ravid M, Lang R, Rachmani R, et al. Long-term renoprotective effect of angiotensin-converting enzyme inhibition in non-insulin-dependent diabetes mellitus: a 7-year follow-up study. Arch Intern Med 1996; 156 (3): 286-289
17. Lewis EJ, Hunsicker LG, Clarke WR, et al. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med 2001; 345 (12): 851-860
18. Lewis EJ, Hunsicker LG, Bain RP, et al. The effect of angiotensin- converting-enzyme inhibition on diabetic nephropathy. The Collaborative Study Group. N Engl J Med 1993; 329 (20): 1456-1462
19. Brenner BM, Cooper ME, de Zeeuw D, et al. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl JMed 2001; 345 (12): 861-869 (Pubitemid 34940825)
20. Parving HH, Lehnert H, Brochner-Mortensen J, et al. The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes. NEngl J Med 2001; 345 (12): 870-878 (Pubitemid 34940826)
21. Pfeffer MA, McMurray JJ, Velazquez EJ, et al. Valsartan, captopril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both. N Engl J Med 2003; 349 (20): 1893-1906
22. Yusuf S, Sleight P, Pogue J, et al. Effects of an angiotensinconverting- enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators. N Engl J Med 2000; 342 (3): 145-153 (Pubitemid 30051645)
23. KDOQI. KDOQI clinical practice guidelines and clinical practice recommendations for diabetes and chronic kidney disease. Am J Kidney Dis 2007; 49 (2 Suppl. 2): S12-154
24. Winkelmayer WC, Fischer MA, Schneeweiss S, et al. Underuse of ACE inhibitors and angiotensin II receptor blockers in elderly patients with diabetes. Am J Kidney Dis 2005; 46 (6): 1080-1087
25. Rosen AB, Karter AJ, Liu JY, et al. Use of angiotensinconverting enzyme inhibitors and angiotensin receptor blockers in high-risk clinical and ethnic groups with diabetes. J Gen Intern Med 2004; 19 (6): 669-675
26. Dunn EJ, Burton CJ, Feest TG. The care of patients with diabetic nephropathy: audit, feedback, and improvement. QJM 1999; 92 (8): 443-449
27. Howard PA, Shireman TI, Dhingra A, et al. Patterns of ACE inhibitor use in elderly Medicaid patients with heart failure. Am J Geriatr Cardiol 2002; 11 (5): 287-294
28. Masoudi FA, Rathore SS, Wang Y, et al. National patterns of use and effectiveness of angiotensin-converting enzyme inhibitors in older patients with heart failure and left ventricular systolic dysfunction. Circulation 2004; 110 (6): 724-731
29. Ahmed A, Allman RM, DeLong JF, et al. Age-related underutilization of angiotensin-converting enzyme inhibitors in older hospitalized heart failure patients. South Med J 2002; 95 (7): 703-710 (Pubitemid 34774466)
30. Frances CD, Noguchi H, Massie BM, et al. Are we inhibited? Renal insufficiency should not preclude the use of ACE inhibitors for patients with myocardial infarction and depressed left ventricular function. Arch Intern Med 2000; 160 (17): 2645-2650
31. Ahmed A, Kiefe CI, Allman RM, et al. Survival benefits of angiotensin-converting enzyme inhibitors in older heart failure patients with perceived contraindications. J Am Geriatr Soc 2002; 50 (10): 1659-1666 (Pubitemid 35192537)
32. Ahmed A, Centor RM, Weaver MT, et al. A propensity score analysis of the impact of angiotensin-converting enzyme inhibitors on long-term survival of older adults with heart failure and perceived contraindications. Am Heart J 2005; 149 (4): 737-743
33. Heart Outcomes Prevention Evaluation Study Investigators. Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE study and MICRO-HOPE substudy. Lancet 2000; 355 (9200): 253-259
34. Ahuja TS, Freeman D, Mahnken Jr JD, et al. Predictors of the development of hyperkalemia in patients using angiotensin- converting enzyme inhibitors. Am J Nephrol 2000; 20 (4): 268-272
35. Winkelmayer WC, Zhang Z, Shahinfar S, et al. Efficacy and safety of angiotensin II receptor blockade in elderly patients with diabetes. Diabetes Care 2006; 29 (10): 2210-2217
36. Bakris GL, Weir MR. Angiotensin-converting enzyme inhibitor-associated elevations in serum creatinine: is this a cause for concern? Arch Intern Med 2000; 160 (5): 685-693
37. Ahmed A. Use of angiotensin-converting enzyme inhibitors in patients with heart failure and renal insufficiency: how concerned should we be by the rise in serum creatinine? J Am Geriatr Soc 2002; 50 (7): 1297-1300
38. Cooke CE, Fatodu H. Physician conformity and patient adherence to ACE inhibitors and ARBs in patients with diabetes, with and without renal disease and hypertension, in a Medicaid managed care organization. J Manag Care Pharm 2006; 12 (8): 649-655